[Anticancer Agents-Related Nephrotoxicity]

Nephrotoxicity is one of the most important complications in cancer patients. In particular, acute kidney injury(AKI)is known to be associated with discontinuing effective oncological treatments, longer hospitalizations and increased costs, a higher risk of death. In addition to AKI, clinical signs associated with nephrotoxicity during anti-cancer agents include chronic kidney disease, proteinuria, hypertension, electrolyte abnormalities, and other characteristic manifestations. It is noted that many of these signs are not only caused by cancer treatment, but also by the cancer itself. Therefore, it is important to carefully recognize whether underlying causes of renal impairment in cancer patients are cancer-related, treatment- related, or both. This review describes the epidemiology and pathophysiology of anti-cancer agents-induced AKI, proteinuria, hypertension, and other characteristic manifestations.